We have detected that you are using an Ad Blocker.
PracticeUpdate is free to end users but we rely on advertising to fund our site. Please consider supporting PracticeUpdate by whitelisting us in your ad blocker.
We have sent a message to the email address you have provided, . If this email is not correct, please update your settings with your correct address.
The email address you provided during registration, , does not appear to be valid. Please update your settings with a valid address before to continue using PracticeUpdate.
Please provide your AHPRA Number to ensure that you are given the correct level of access to our site.

Journal Scan / Research · July 01, 2020

Effectiveness and Safety of Pyrotinib in Patients With HER2+ Metastatic Breast Cancer

Frontiers in Oncology


Additional Info

Frontiers in Oncology
Effectiveness and Safety of Pyrotinib, and Association of Biomarker With Progression-Free Survival in Patients With HER2-Positive Metastatic Breast Cancer: A Real-World, Multicentre Analysis
Front Oncol 2020 Jun 01;[EPub Ahead of Print], Q Chen, D Ouyang, M Anwar, N Xie, S Wang, P Fan, L Qian, G Chen, E Zhou, L Guo, X Gu, B Ding, X Yang, L Liu, C Deng, Z Xiao, J Li, Y Wang, S Zeng, J Hu, W Zhou, B Qiu, Z Wang, J Weng, M Liu, Y Li, T Tang, J Wang, H Zhang, B Dai, W Tang, T Wu, M Xiao, X Li, H Liu, L Li, W Yi, Q Ouyang

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.

Further Reading